USAR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
BUY now (speculative growth). The trend is technically bullish (SMA_5 > SMA_20 > SMA_200) and sentiment has improved materially after major U.S. government support and large PIPE financing de-risked funding. Options positioning is strongly call-skewed (bullish). Near-term risk is headline/policy whipsaw and an earnings event on 2026-02-05, but given you’re impatient and unwilling to wait for an “optimal” pullback, current levels around 22.7 still look like a good entry versus raised Street targets (33–45).
Price/Trend: Post-market 22.68 (+0.58%), still below the pivot at 23.588, implying some near-term overhead resistance before a cleaner breakout. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), which supports an uptrend bias. Momentum: MACD histogram is positive (0.406) but contracting—bull trend intact, yet momentum is cooling after the recent move. RSI_6 ~51.5 is neutral, suggesting the stock is not immediately overbought or oversold. Levels: Support S1 ~17.47 (key downside line), resistance starts near pivot 23.59 then R1 ~29.71. The setup favors buyers as long as price holds above the mid/low-20s and especially above ~17.5 on any selloff.
Intellectia Proprietary Trading Signals
• Major U.S. government support: federal funding plus a large CHIPS-related loan/LOI narrative improves confidence in execution financing.
• Large PIPE raise and improved capital availability meaningfully reduce near-term funding risk and shifts the debate to execution.
• Multiple analysts aggressively raised price targets (to 33–45 range) following the funding package and accelerated commercialization schedule.
• Upcoming earnings (2026-02-05 after hours) can act as a catalyst if progress/milestones are reaffirmed.
means large drawdowns are possible on adverse headlines even in an uptrend.
Latest provided quarter: 2025/Q3. The company remains pre-revenue (Revenue: 0, 0% YoY). Losses are still substantial (Net Income: -156.68M; EPS: -1.53). Despite the YoY change showing “improvement” in the loss metrics in the snapshot, the key takeaway is that fundamentals are currently driven by funding and execution milestones rather than operating earnings.
Recent trend: decisively more bullish. From late Jan 2026, multiple firms raised price targets sharply while reiterating Buy/Overweight (Cantor to 35, Roth to 35, Canaccord to 33, Benchmark to 45; Benchmark previously had 15 on 1/22 before the funding acceleration updates). Wall Street pros: Funding risk reduced; accelerated operational schedule; vertically integrated magnet supply chain thesis; large long-term EBITDA potential if milestones are met. Wall Street cons: Structural deficiency versus peers if there are no price floors/offtake guarantees; execution risk remains the core risk; policy uncertainty can pressure the entire rare-earth complex. Politicians/Congress: No recent congress trading data available in the last 90 days.
